Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation

医学 拜瑞妥 达比加群 华法林 危险系数 心房颤动 阿哌沙班 内科学 队列 倾向得分匹配 队列研究 冲程(发动机) 心脏病学 比例危险模型 麻醉 置信区间 工程类 机械工程
作者
Dae Hyun Kim,Ajinkya Pawar,Joshua J. Gagne,Lily G. Bessette,Hemin Lee,Robert J. Glynn,Sebastian Schneeweiß
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:174 (9): 1214-1223 被引量:85
标识
DOI:10.7326/m20-7141
摘要

Background: The role of differing levels of frailty in the choice of oral anticoagulants for older adults with atrial fibrillation (AF) is unclear. Objective: To examine the outcomes of direct oral anticoagulants (DOACs) versus warfarin by frailty levels. Design: 1:1 propensity score–matched analysis of Medicare data, 2010 to 2017. Setting: Community. Patients: Medicare beneficiaries with AF who initiated use of dabigatran, rivaroxaban, apixaban, or warfarin. Measurements: Composite end point of death, ischemic stroke, or major bleeding by frailty levels, defined by a claims-based frailty index. Results: In the dabigatran–warfarin cohort (n = 158 730; median follow-up, 72 days), the event rate per 1000 person-years was 63.5 for dabigatran initiators and 65.6 for warfarin initiators (hazard ratio [HR], 0.98 [95% CI, 0.92 to 1.05]; rate difference [RD], −2.2 [CI, −6.5 to 2.1]). For nonfrail, prefrail, and frail persons, HRs were 0.81 (CI, 0.68 to 0.97), 0.98 (CI, 0.90 to 1.08), and 1.09 (CI, 0.96 to 1.23), respectively. In the rivaroxaban–warfarin cohort (n = 275 944; median follow-up, 82 days), the event rate per 1000 person-years was 77.8 for rivaroxaban initiators and 83.7 for warfarin initiators (HR, 0.98 [CI, 0.94 to 1.02]; RD, −5.9 [CI, −9.4 to −2.4]). For nonfrail, prefrail, and frail persons, HRs were 0.88 (CI, 0.77 to 0.99), 1.04 (CI, 0.98 to 1.10), and 0.96 (CI, 0.89 to 1.04), respectively. In the apixaban–warfarin cohort (n = 218 738; median follow-up, 84 days), the event rate per 1000 person-years was 60.1 for apixaban initiators and 92.3 for warfarin initiators (HR, 0.68 [CI, 0.65 to 0.72]; RD, −32.2 [CI, −36.1 to −28.3]). For nonfrail, prefrail, and frail persons, HRs were 0.61 (CI, 0.52 to 0.71), 0.66 (CI, 0.61 to 0.70), and 0.73 (CI, 0.67 to 0.80), respectively. Limitations: Residual confounding and lack of clinical frailty assessment. Conclusion: For older adults with AF, apixaban was associated with lower rates of adverse events across all frailty levels. Dabigatran and rivaroxaban were associated with lower event rates only among nonfrail patients. Primary Funding Source: National Institute on Aging.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘿嘿发布了新的文献求助10
刚刚
rioo完成签到,获得积分10
刚刚
科研通AI5应助飘逸妙柏采纳,获得10
刚刚
流苏发布了新的文献求助10
1秒前
慕青应助skf采纳,获得10
1秒前
1秒前
1秒前
dd完成签到,获得积分10
2秒前
李健应助时尚的八宝粥采纳,获得10
2秒前
2秒前
3秒前
长公主发布了新的文献求助10
3秒前
听雨发布了新的文献求助10
3秒前
3秒前
鹿lu发布了新的文献求助10
4秒前
摆烂好爽发布了新的文献求助20
5秒前
虚心向梦发布了新的文献求助10
5秒前
Hello应助linkman采纳,获得10
5秒前
脑洞疼应助Loone采纳,获得10
6秒前
剑九黄发布了新的文献求助10
6秒前
李振博发布了新的文献求助10
7秒前
CodeCraft应助sunjiaxing采纳,获得10
7秒前
ysy发布了新的文献求助10
7秒前
CJY发布了新的文献求助30
7秒前
啥也做不出来的小谭完成签到,获得积分10
8秒前
8秒前
xx完成签到 ,获得积分10
9秒前
猫小曼发布了新的文献求助30
10秒前
10秒前
10秒前
10秒前
坦率的含海完成签到,获得积分10
11秒前
是玥玥呀完成签到,获得积分20
11秒前
11秒前
李健的小迷弟应助ysy采纳,获得10
12秒前
科研通AI5应助可爱柠檬采纳,获得10
12秒前
12秒前
二斤瓜子完成签到,获得积分10
12秒前
12秒前
量子星尘发布了新的文献求助10
12秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974426
求助须知:如何正确求助?哪些是违规求助? 3518788
关于积分的说明 11195842
捐赠科研通 3254946
什么是DOI,文献DOI怎么找? 1797649
邀请新用户注册赠送积分活动 877037
科研通“疑难数据库(出版商)”最低求助积分说明 806130